BioPharma « Terug naar discussie overzicht

HIV; waarom lager?

1.470 Posts, Pagina: « 1 2 3 4 5 6 ... 40 41 42 43 44 45 46 47 48 49 50 ... 70 71 72 73 74 » | Laatste

Omlaag ↓

[verwijderd] 27 november 2006 12:29

Aandeelhoudersvergadering op 15/12/06 - Ben benieuwd of daar nog iets nieuws uitkomt.

[verwijderd] 30 november 2006 15:58

Ja, HIV, waarom wéér lager?

[verwijderd] 30 november 2006 16:59

Hiv,kan bijna niet lager...

[verwijderd] 30 november 2006 18:12

Ook dit fijne aandeel is met geen cent vooruit te branden, de inflatie van de dollar gaat 100 x sneller

[verwijderd] 30 november 2006 18:23

quote:
duffehenk schreef:
Ook dit fijne aandeel is met geen cent vooruit te branden, de inflatie van de dollar gaat 100 x sneller

Duffe Henk is wakkere Henk en wordt zelfs actief. Alle draadjes worden met een bezoek vereerd!

[verwijderd] 1 december 2006 14:54

Calypte Announces Donation of its Aware(TM) HIV-1/2 Oral Fluid Rapid Tests
Gifts to Kenya and UAE in Honor of World AIDS Day
LAKE OSWEGO, Ore., Dec. 1 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market announced today that it is donating 10,000 Aware(TM) HIV-1/2 OMT (oral fluid) rapid tests to the Ministry of Health for the Republic of Kenya, and, through its Middle East distributor, Joseph and Gionis, LLC, 5,000 tests to the government of the United Arab Emirates (UAE). These donations are in honor of World AIDS Day.

Calypte's Aware(TM) HIV-1/2 oral fluid rapid tests are approved for sale in both the Republic of Kenya and the UAE, which allows for immediate use of these donated tests.

Professor Jeckoniah Ndinya-Achola, Associate Professor and Consultant Clinical Microbiologist at Kenyatta National Hospital, University of Nairobi noted "under my direct supervision, the Laboratories of the Department of Medical Microbiology, University of Nairobi at Kenyatta National Hospital campus have participated in the evaluation of Calypte's rapid testing device for HIV detection using oral fluid specimens. We have found this device very sensitive and accurate in detecting HIV infection. Besides its ability to detect HIV with the same accuracy as blood based tests, other unique features of this test are its being non-invasive and the relative ease of sample collection. The device is ideal for use by individuals who would like utmost confidentiality and those who would like to be spared the discomfort of blood collection."

Dr. Walid Yousef, vice president of Joseph and Gionis stated, "We have 100,000 of Calypte's Aware(TM) HIV-1/2 oral fluid rapid OTC tests in transit to Dubai from Calypte's Thailand manufacturing site. Joseph and Gionis and Bin Salem GTE, our UAE representative, are working with the UAE government in their trial of free voluntary HIV testing for government employees. Joseph and Gionis will donate 5,000 test kits for the initial trial program. This begins the official launch of the HIV test kit with the December, 2006 World AIDS Day."

Mr. Roger I. Gale, Calypte's Chairman and Chief Executive Officer commented, "We are pleased to share our Aware(TM) HIV-1/2 oral fluid rapid tests in honor of World AIDS Day as we now have approvals in several key countries where such a non-invasive test can help. The relationships we are building with these donations are important to our efforts. Professor Ndinya is well respected and widely considered a dean in the HIV field, as one of the first to discover HIV in Africa. We also have the utmost respect for the work that Joseph and Gionis is doing in the Middle East. Their support on World Aids Day reflects on their attitude in dealing with this pandemic. We look forward to sales of our products expanding into many additional countries throughout the world in 2007 as we do our part in the fight against HIV/AIDS."

About Kenya and the Sub-Saharan Africa Region:

According to the December 2005 AIDS Epidemic Update, published jointly by the Joint United Nations Programme on HIV/AIDS ("UNAIDS") and the World Health Organization, Sub-Saharan Africa has just over 10% of the world's population, but is home to more than 60% of all people living with HIV -- some 25.8 million. In 2005, an estimated 3.2 million people in the region became newly infected, while 2.4 million adults and children died of AIDS.

Kenya has a population of approximately 34 million people of whom approximately 1.3 million live with AIDS. An estimated 140,000 adults and children died of AIDS-related illnesses in 2005. Kenya has a 5-year strategic plan targeting this disease and is one of three countries in the region that has seen a decline in its prevalence. Kenya's HIV prevalence rate in adults has fallen to 6.1% in 2004 from a peak of 10% in the mid-1990s. (Kenya HIV and AIDS Data Booklet, 2005)

About the UAE and the Middle East Region:

This region has a population of approximately 500 million people. According to the same December 2005 UNAIDS report, the advance of AIDS in the Middle East and North Africa has continued, with latest estimates showing that 67,000 people became infected with HIV in 2005. Approximately 510,000 people are living with HIV in the region and an estimated 58,000 adults and children died of AIDS-related illnesses in 2005.

[verwijderd] 6 december 2006 15:10

Calypte, in Washington, DC, Presents the 10,000 Oral Fluid Rapid HIV Test Donation to the Embassy of Kenya
LAKE OSWEGO, Ore., Dec. 6 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market, presented in Washington, DC, 10,000 of its Aware(TM) HIV-1/2 OMT (oral fluid) rapid tests to Ms. Lily Sambu, Deputy Chief of Mission to the Embassy of Kenya. The event took place in the U.S. House Cannon office building hosted by U.S. Congresswoman Darlene Hooley (D-OR) who praised Calypte's donation. "For too long we've seen the effects of HIV/AIDS in the world. It is time we find a better way to test individuals without fear of accidental infection," said Representative Hooley. "With Calypte's donation to Kenya, we know there will be more people tested and finding out their status."

Receiving the tests on behalf of His Excellency Peter Ogego, Kenyan Ambassador to the United States, Ms. Sambu said, "This method of testing is wonderful. With these tests one does not need a professional to assist you, which cut down on the stigma of a blood test." Ms. Sambu further added, "We will work with Calypte to further their endeavor with the Ministry of Health."

His Excellency Peter Ogego commented, "While we still await any possible breakthroughs in the search for the HIV/AIDS vaccine, jointly conducted by KAVI (the Kenya's AIDS Virus Initiative) and IAVI (the International AIDS Virus Initiative), the Aware(TM) HIV-1/2 OMT rapid tests are able to help our people to determine their status for subsequent treatment, if they are positive."

"It would therefore be an important facility or tool to identify who needs to be treated -- the sooner the better -- and thereby making an important contribution to the fight against HIV/AIDS," His Excellency Peter Ogego concluded.

Also congratulating Calypte on their donation was U.S. Congressman John Boozman (R-AR) who sits on the House Africa Subcommittee of the International Relations Committee. Representative Boozman is also chairman of the Ivory Coast and West Africa caucuses, and a member of the Kenya Caucus.

"Knowledge is a key component in combating the spread of HIV/AIDS across the world, and especially in Africa," Representative Boozman said. "Any way to make the diagnosis of HIV easier will allow for the proper care and treatment of infected persons, thus resulting in controlling the spread of the virus.

"I applaud Calypte and the efforts of my friend from Oregon to make this humanitarian gesture possible," Representative Boozman added.

Other Members of Congress congratulating Calypte's donation were Congressman Henry Cuellar (D-TX) of Laredo and Congressman Danny Davis (D-IL) of Chicago.

Calypte is headquartered in Congresswoman Hooley's district in Lake Oswego, Oregon, and coordinated the donation with the Congresswoman's office. A champion in the fight against HIV/AIDS, Congresswoman Hooley has continually shown an eagerness to help U. S. companies expand the use of their products into Africa and other affected areas. Calypte's non-invasive rapid HIV tests are approved in Kenya, which will permit their immediate use.

Mr. Roger I. Gale, Calypte's Chairman and Chief Executive Officer commented, "We are pleased to have the support of the Ambassador, our local Congresswoman and other Members of Congress. We believe we are involved in an important humanitarian effort and it is through the support of these important individuals and their organizations that we can best assist in the global fight against AIDS. This donation to the Republic of Kenya, where our products are approved for sale and use, is a way to provide key thought centers with the ability to diagnose HIV/AIDS in situations where such a non-invasive test can be of help. Without the discomfort and risk of a blood test, voluntary testing rates have been shown to increase significantly. One of the fundamental aspects of HIV intervention is identifying infected individuals so that they may be counseled and referred to therapy. We are pleased to lead the way in this effort with our Aware(TM) HIV-1/2 oral fluid rapid test."

Leuk bericht, maar of dit van invloed zal zijn op de koers? Denk het niet, net zoals al die overige positieve berichten dat niet hadden..
Misschien een centje omhoog vandaag

gustaaf1e 6 december 2006 20:22

Wellicht iets meer naamsbekendheid door de presentatie.
G

[verwijderd] 9 december 2006 12:24

Risk Alert Level for CBMC.OB "LOW"

tinyurl.com/y4z66l

[verwijderd] 12 december 2006 14:38

Calypte Announces First Russian Sales Order
LAKE OSWEGO, Ore., Dec. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market announced today that it has received the initial order from its distributor in Russia, Ordynka Investments Limited, for 25,000 of its Aware(TM) Oral Fluid (OMT) HIV-1/2 rapid tests for the OTC market in the Russian Federation. This product, designed for use in non-clinical settings, permits significantly greater access to HIV testing.

Mr. Vladimir Saveliev, Managing Director of Ordynka Investments Limited, stated "We are happy to be working with Calypte in the hope to be able to help Russia in its fight against the prevention of the spread of the fast growing HIV/AIDS epidemic and this initial order of 25,000 test kits should help the cause. In addition to being safe and painless, oral fluid sampling is very efficient and thereby facilitates high-throughput testing in settings such as the military, prisons, schools and universities. Additionally, oral fluid sampling facilitates testing in many settings, such as outreach or prevalence surveys in remote locations, where drawing blood is difficult or even impossible."

Mr. Saveliev continued, "We intend to deliver no less than 500,000 tests to the Russian Federation over the next 12 months and are confident that the need for these products can be greater than this."

One of the fundamental aspects of HIV intervention is the identification of infected individuals so that they may be counseled and referred to therapy. Although a portion of HIV infections may be identified through a variety of mandated, institutionalized testing programs, the identification of infections in the general population relies largely on the public's voluntary participation in testing programs.

Mr. Roger Gale, Calypte's Chairman and Chief Executive Officer commented, "While HIV testing in Russia is already extensive, our recently approved AwareTM HIV-1/2 OMT (oral fluid) rapid test overcomes several barriers to testing as it is a non-invasive test. As such, we believe it will form the basis for a quality post-testing counseling system - for prevention as well as treatment."

Mr. Gale continued, "We have worked closely with Marr Technologies B.V. ("Marr"), our strategic partner and the Company's largest investor, whose principals come from this region, and we are optimistic that their contacts in the region will maximize our ability to serve the needs of the Russian Federation in its plans to contain the HIV/AIDS epidemic."

About the Russian Federation:

The Russian Federation is home to 143 million people. According to the 2006 Report on the Global AIDS Epidemic jointly published by the Joint United Nations Programme on HIV/AIDS ("UNAIDS") and the World Health Organization ("WHO"), there are 940,000 people living with AIDS in the Russian Federation (as of the end of 2005). According to the WHO, the number of people officially registered with HIV increased almost 100-fold in the past eight years from 3,623 cases in 1997 to about 350,000 cases by the end of 2005.

The 2006 Report notes that Russia now has an HIV/AIDS epidemic that is both the biggest in Europe and said to be the fastest growing in the world. The Russian AIDS epidemic has now reached the stage where it is propagating out of high risk groups and into the general population. According to the 2006 report by Transatlantic Partners Against AIDS ("TPAA") titled Key Facts About HIV/AIDS in the Russian Federation, the proportion of Russia's newly reported HIV infections acquired through heterosexual intercourse has grown from 6% in 2001 to close to 27% in 2004. Russia is taking action to reverse this trend and Calypte believes that its non-invasive OTC rapid test can have an immediate positive impact on the effort to increase diagnosis and treatment of HIV/AIDS in this region.

Wij zijn benieuwd!!

P.

[verwijderd] 14 december 2006 19:10

Lijkt te keren...0.08

[verwijderd] 14 december 2006 19:23

Als ie nog even kan wachten graag, lig nog op 0,07 heb nog maar 1/3 binnen..

gustaaf1e 18 december 2006 14:57

O.a. interessant nieuws over stand van zaken Chinese FDA mbt. hiv-test.

Calypte Announces Results of 2006 Annual Stockholders' Meeting

CEO Comments on Progress Toward Chinese SFDA Approval

LAKE OSWEGO, Ore., Dec. 18 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market today announced the results of its 2006 Annual Stockholders' Meeting held on December 15, 2006 at its headquarters location in Lake Oswego, Oregon.

The Company reported that its stockholders approved the following proposals:

1. To re-elect the five current directors of the Company; Mr. Roger I.
Gale, Chairman and Chief Executive Officer; Mr. John J. DiPietro; Mr.
Paul E. Freiman; Dr. Julius R. Krevans, M.D; and Mr. Maxim A. Soulimov,
who will hold office until the next Annual Meeting of Stockholders or
until their successors are elected; and

2. To ratify the appointment by the Audit Committee and the Board of
Directors of Odenberg Ullakko Muranishi & Co. LLP ("OUM") as the
independent registered public accounting firm to audit the Company's
financial statements for the fiscal year ending December 31, 2006.

Mr. Roger Gale provided an update to the Stockholders in attendance, commenting on recent sales progress in the regions where the Company has approval of its Aware(TM) HIV-1/2 OMT (oral fluid) rapid test, specifically Russia, the Middle East and Africa. When asked about a sales outlook, Mr. Gale acknowledged the difficulty of estimating the results from these early- stage efforts, but indicated that the company is internally forecasting sales in the range of $4.5 million to $4.7 million for 2007. Although the Company does not expect this sales level to result in cash flow breakeven, it is optimistic that sales could exceed this level as several of the initiatives, including high-profile charities, certain private sector groups, and various government agencies could each result in significant sales demand.

Mr. Gale was also optimistic concerning the progress in China, stating "Dr. Ron Mink, Calypte's Chief Science Officer, was invited to attend the Chinese State Food and Drug Administration's ("SFDA") Expert Panel Meeting held on December 4, 2006 in Beijing, China, where the Company made a presentation and answered technical questions before a panel of 10 experts regarding its Aware(TM) HIV-1/2 OMT test. The SFDA has an approval process similar to that of the U.S. FDA and in that respect, this presentation is one of the later parts of the process. Although the panel needs to review the inputs from the meeting as well as other information in reaching its decision on our application, we think the meeting went well and that we satisfactorily addressed all of the panel's questions. We will continue to keep you informed as we prepare for our sales launch in China."

Mr. Gale continued, "Our factory in China has been readied for the production of our Aware(TM) products; equipment is in place and personnel have been trained. When we have completed our GMP approval, we expect to be able to supply both the Chinese and export markets, as sales demand dictates. We have a planned capacity of approximately 10 million tests per month and, through our joint venture, own land for expansion as needed. We are optimistic about our opportunity to serve the Chinese market and other key regions where the HIV/AIDS pandemic is expected to grow over the next several years. We believe our efforts to help identify HIV infections in a simple, quick and non-invasive way will be a part of the solution in helping to bring the disease under control."

About Calypte Biomedical

[verwijderd] 18 december 2006 19:15

Koers doet vooralsnog niets op dit nieuws, betekent wel dat ik mn stukken binnen heb op 0,07.
En nu maar wachten op approval Chinese FDA..

gustaaf1e 18 december 2006 19:52

Nudie, ik denk dat je een goed koopmoment hebt gekozen.
G

[verwijderd] 18 december 2006 20:26

hoe ver kunnen we reiken bij chinese goedkeuring denken jullie.Heb vandaag ook bijgetankt.

Weten julie wat de verkoopprijs van die tests moet worden.Ze denken er 10kk per maand te kunnen slijten in china.

[verwijderd] 18 december 2006 21:25

quote:
1gustaaf schreef:
Nudie, ik denk dat je een goed koopmoment hebt gekozen.
G

lag daar al vanaf 4 december, heeft even geduurd dus voordat de stukken binnen waren, ik heb geduld tot beslissing China (zou 15 november + max 100 dagen moeten zijn, dus zeg eind februari).
koersdoel geen idee, maar verwacht toch in eerste instantie minimaal een piek naar 0,20..

[verwijderd] 23 december 2006 13:46

Gisteren low 0,062, 43K gegaan op die koers.. lijkt erop dat er nog gekocht kan gaan worden op koersen 0,06 en lager..

[verwijderd] 4 januari 2007 22:15

Handel vandaag tussen 0,072 en 0,075, lijkt iets omhoog te willen.. wachten is op nieuws Chinese FDA.

[verwijderd] 4 januari 2007 22:17

Zag dat ik weer kan handelen bij alex, was een tijdje geleden niet mogelijk.

1.470 Posts, Pagina: « 1 2 3 4 5 6 ... 40 41 42 43 44 45 46 47 48 49 50 ... 70 71 72 73 74 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 899,24 +9,55 +1,07% 18:05


Germany40^	22.679,40	+1,57%
BEL 20	4.386,42	+2,09%
Europe50^	5.361,22	+0,97%
US30^	41.480,30	+0,11%
Nasd100^	19.672,30	+1,53%
US500^	5.619,02	+0,87%
Japan225^	37.182,20	+1,75%
Gold spot	2.939,57	+0,77%
EUR/USD	1,0910	-0,05%
WTI	67,67	+1,67%